Overview

Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The underlying goal of this study is to assess [18F]-FMH3 PET imaging as a tool to evaluate the activity of the H3 receptor in the brain of Alzheimer Disease (AD) research participants
Phase:
Early Phase 1
Details
Lead Sponsor:
Institute for Neurodegenerative Disorders
Treatments:
Histamine
Histamine phosphate